Intravitreal bevacizumab for exudative retinal detachment post laser therapy for retinopathy of prematurity.
Retinopathy of prematurity (ROP), a leading cause of pediatric blindness, predominantly affects premature and low-birth-weight infants. Although many cases are self-limiting, a minority progress to retinal detachment despite treatment. Exudative retinal detachments, although uncommon, have been reported after conventional laser therapy.(1-3) We report 2 cases of exudative retinal detachment after laser therapy for prethreshold and threshold ROP that responded favourably to a series of intravitreal bevacizumab injections.
Department of Ophthalmology, University of Alberta, Edmonton Alberta. Electronic address: dehmann@ualberta.ca.
David
D
Ehmann
Department of Ophthalmology, University of Alberta, Edmonton Alberta.
Mark
M
Greve
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D005122:Exudates and Transudates; D005260:Female; D005865:Gestational Age; D006801:Humans; D052577:Infant, Extremely Low Birth Weight; D007231:Infant, Newborn; D058449:Intravitreal Injections; D017075:Laser Coagulation / Q000009:adverse effects*; D008297:Male; D012163:Retinal Detachment / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology; D012178:Retinopathy of Prematurity / Q000601:surgery*; D014463:Ultrasonography; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab